Prof. Dr. Martin Früh
Medizinische Onkologie und Hämatologie · Dept. I
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. Lung Cancer 2019
Mar 5, 2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort
Mar 5, 2019Lung Cancer 2019
Schmid Sabine, Aeppli Stefanie, Früh Martin
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. Lung Cancer 2019; 130:149-155.
Feb 19, 2019Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Feb 19, 2019Lung Cancer 2019; 130:149-155
Schmid Sabine, Jochum Wolfram, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli Stefanie, Klingbiel D, Früh Martin
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
Feb 14, 2019A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Feb 14, 2019Clin Cancer Res 2019; 25:3026-3034
Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Papachristofilou A, Kallen K, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H, Koch S, Gnad-Vogt U, Griesinger F, Geißler M, Bischoff H, Hipp M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019; 7:38.
Feb 8, 2019Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Feb 8, 2019J Immunother Cancer 2019; 7:38
Papachristofilou Alexandros, Kallen Karl-Josef, Fotin-Mleczek Mariola, Schröder Andreas, Scheel Birgit, Muth Anke, Seibel Tobias, Stosnach Claudia, Doener Fatma, Hong Henoch S, Koch Sven D, Gnad-Vogt Ulrike, Griesinger Frank, Geißler Michael, Bischoff Helge, Hipp Madeleine M, Klinkhardt Ute, Früh Martin, Sebastian Martin, Weiss Christian, Pless Miklos, Cathomas Richard, Hilbe Wolfgang, Pall Georg, Wehler Thomas, Alt Jürgen, Zippelius Alfred
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Putora P, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost E, Van Houtte P, Westeel V, Widder J, Mornex F, Nestle U, McDonald F, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, De Ruysscher D. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol 2019; 133:163-166.
Jan 31, 2019Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Jan 31, 2019Radiother Oncol 2019; 133:163-166
Putora Paul Martin, Novello Silvia, O'Brien Mary, Paz Ares Luis, Peeters Stephanie, Pöttgen Christoph, Ramella Sara, Reck Martin, Slotman Ben, Troost Esther G C, Van Houtte Paul, Westeel Virginie, Widder Joachim, Mornex Francoise, Nestle Ursula, McDonald Fiona, Glatzer Markus, Belderbos Jose, Besse Benjamin, Blackhall Fiona, Califano Raffaele, Cappuzzo Federico, de Marinis Filippo, Dziadziuszko Rafal, Felip Enriqueta, Faivre-Finn Corinne, Früh Martin, Garrido Pilar, Le Pechoux Cecila, De Ruysscher Dirk
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
Jan 25, 2019Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Jan 25, 2019Cancer Chemother Pharmacol 2019; 83:763-774
Hoemme Alexander, Driessen Christoph, Früh Martin, Thürlimann Beat, Wälti Thomas, von Kameke Alexander, Lehner Claudia, Strasser Florian, Krähenbühl Stephan, Haschke Manuel, Barth Holger, Jörger Markus
Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys
Mousavi S, Schmid S, Cerny T, Früh M. Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys. Swiss Med Wkly 2018; 148:w14708.
Dec 30, 2018Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys
Dec 30, 2018Swiss Med Wkly 2018; 148:w14708
Mousavi Seyed Mohsen, Schmid Sabine, Cerny Thomas, Früh Martin
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
Nov 8, 2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Nov 8, 2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
Griesinger F, Gautschi O, Früh M, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J. [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. Pneumologie 2018; 72:774-781.
Nov 8, 2018[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
Nov 8, 2018Pneumologie 2018; 72:774-781
Griesinger F, Gautschi O, Früh Martin, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J
Multidisciplinary treatment of lung cancer in older patients: A review
Radovic M, Kanesvaran R, Rittmeyer A, Früh M, Minervini F, Glatzer M, Putora P. Multidisciplinary treatment of lung cancer in older patients: A review. J Geriatr Oncol 2018; 10:405-410.
Oct 3, 2018Multidisciplinary treatment of lung cancer in older patients: A review
Oct 3, 2018J Geriatr Oncol 2018; 10:405-410
Radovic Marco, Kanesvaran Ravindran, Rittmeyer Achim, Früh Martin, Minervini Fabrizio, Glatzer Markus, Putora Paul Martin
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Früh M, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Weder W, Stahel R, Matzinger O, Betticher D, Stupp R, Xyrafas A, Peters S, Ris H, Mirimanoff R, Ochsenbein A, Schmid R, Pless M. Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). J Thorac Oncol 2018
Sep 26, 2018Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Sep 26, 2018J Thorac Oncol 2018
Früh Martin, Guckenberger Matthias, Rothschild Sacha I, Lardinois Didier, Mach Nicholas, Mark Michael, Gautschi Oliver, Thierstein Sandra, Biaggi Rudolf Christine, Weder Walter, Stahel Rolf A, Matzinger Oscar, Betticher Daniel C, Stupp Roger, Xyrafas Alexandros, Peters Solange, Ris Hans Beat, Mirimanoff Rene Olivier, Ochsenbein Adrian F, Schmid Ralph, Pless Miklos
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018
Aug 31, 2018Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Aug 31, 2018Cancer Immunol Immunother 2018
Schmid Sabine, Jochum Wolfram, Klingbiel Dirk, Desbiolles Lotus, Leschka Sebastian, Flatz Lukas, Krapf Mirjam, Li Qiyu, Diem Stefan, Früh Martin
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrausch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018
Aug 21, 2018Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Aug 21, 2018J Thorac Oncol 2018
Metaxas Yannis, Froesch Patrizia, Löffler-Baumann Melanie, Pratsch-Peter Susanne, Russell Prudence, Mingrone Walter, Savic Spasenija, Thapa Bibhusal, Früh Martin, Pless Miklos, von Moos Roger, Mauti Laetitia, O'Byrne Kenneth, Petrausch Ulf, Wolleb Sybille, Rivalland Gareth, Klingbiel Dirk, Kao Steven, Schmid Sabine, Nowak Anna K, Gautschi Oliver, Bartnick Tammo, Hughes Brett G, Bouchaab Hasna, Rothschild Sacha, Pavlakis Nick, John Thomas
Genomic Features of Response to Combination Immunotherapy in Lung Cancer
Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell 2018; 33:791-793.
May 14, 2018Genomic Features of Response to Combination Immunotherapy in Lung Cancer
May 14, 2018Cancer Cell 2018; 33:791-793
Früh Martin, Peters Solange
Immune checkpoint inhibitors and small cell lung cancer: what's new?
Schmid S, Früh M. Immune checkpoint inhibitors and small cell lung cancer: what's new?. J Thorac Dis 2018; 10:S1503-S1508.
May 1, 2018Immune checkpoint inhibitors and small cell lung cancer: what's new?
May 1, 2018J Thorac Dis 2018; 10:S1503-S1508
Schmid Sabine, Früh Martin
EML4-ALK Variant Affects ALK Resistance Mutations
Früh M, Peters S. EML4-ALK Variant Affects ALK Resistance Mutations. J Clin Oncol 2018; 36:1257-1259.
Mar 1, 2018EML4-ALK Variant Affects ALK Resistance Mutations
Mar 1, 2018J Clin Oncol 2018; 36:1257-1259
Früh Martin, Peters Solange
Immune checkpoint inhibitors and small cell lung cancer: what’s new?
Schmid S, Früh M. Immune checkpoint inhibitors and small cell lung cancer: what’s new?. Journal of theoracic disease 2018; 10:1503-1508.
Jan 14, 2018Immune checkpoint inhibitors and small cell lung cancer: what’s new?
Jan 14, 2018Journal of theoracic disease 2018; 10:1503-1508
Schmid Sabine, Früh Martin
The role of radiation therapy in the management of small cell lung cancer
Glatzer M, Schmid S, Radovic M, Früh M, Putora P. The role of radiation therapy in the management of small cell lung cancer. Breathe (Sheff) 2017; 13:e87-e94.
Dec 1, 2017The role of radiation therapy in the management of small cell lung cancer
Dec 1, 2017Breathe (Sheff) 2017; 13:e87-e94
Glatzer Markus, Schmid Sabine, Radovic Marco, Früh Martin, Putora Paul Martin
Treatment of limited disease small cell lung cancer: the multidisciplinary team
Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora P. Treatment of limited disease small cell lung cancer: the multidisciplinary team. Eur Respir J. 2017; 50
Aug 24, 2017Treatment of limited disease small cell lung cancer: the multidisciplinary team
Aug 24, 2017Eur Respir J. 2017; 50
Glatzer Markus, Rittmeyer Achim, Müller Joachim, Opitz Isabelle, Papachristofilou Alexandros, Psallidas Ioannis, Früh Martin, Born Diana, Putora Paul Martin